Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.6
3.6
Journals
Diagnostics
Special Issues
Advances in Diagnosis and Treatment of Hepatobiliary Pancreatic Disorders
share announcement

Advances in Diagnosis and Treatment of Hepatobiliary Pancreatic Disorders

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: 31 August 2024 | Viewed by 375

Special Issue Editors

Dr. Ioannis A. Ziogas

E-Mail Website
Guest Editor
Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
Interests: pediatric transplantation; pediatric surgery; liver transplantation; hepatobiliary surgery
Prof. Dr. Georgios Tsoulfas

E-Mail Website
Guest Editor
Department of Transplantation Surgery, Aristotle University School of Medicine, Thessaloniki, Greece
Interests: liver transplantation; hepatobiliary surgery; pancreatic surgery; kidney transplantation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Hepatobiliary and pancreatic disorders are being diagnosed with an increasing incidence over the past years. The most common primary hepatobiliary malignancies are hepatocellular carcinoma and cholangiocarcinoma, while the most common primary pancreatic malignancy is adenocarcinoma, and they account for a significant proportion of cancer-related mortality worldwide. The armamentarium of clinicians regarding the diagnosis and management of such malignancies or other benign hepatobiliary and pancreatic disorders is rapidly evolving, which allows for improved outcomes for these patients. Therefore, the current Special Issue aims to present a collection of articles that highlight the most up-to-date advancements in the diagnosis and management of diseases of the liver, bile ducts and pancreas. Contributions with original research articles, reviews and case reports or series are welcome.

Dr. Ioannis A. Ziogas
Prof. Dr. Georgios Tsoulfas
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • liver cancer
  • pancreatic cancer
  • hepatobiliary disorders
  • pancreatic disorders
  • liver transplantation

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Other

13 pages, 496 KiB  
Systematic Review
Robotic Stereotactic Body Radiation Therapy for Oligometastatic Liver Metastases: A Systematic Review of the Literature and Evidence Quality Assessment
by Ilektra Kyrochristou, Ilias Giannakodimos, Maria Tolia, Ioannis Georgakopoulos, Nikolaos Pararas, Francesk Mulita, Nikolaos Machairas and Dimitrios Schizas
Diagnostics 2024, 14(10), 1055; https://doi.org/10.3390/diagnostics14101055 - 19 May 2024
Viewed by 182
Abstract
Introduction: The role of stereotactic body radiation therapy (SBRT) as a locally effective therapeutic approach for liver oligometastases from tumors of various origin is well established. We investigated the role of robotic SBRT (rSBRT) treatment on oligometastatic patients with liver lesions. Material and [...] Read more.
Introduction: The role of stereotactic body radiation therapy (SBRT) as a locally effective therapeutic approach for liver oligometastases from tumors of various origin is well established. We investigated the role of robotic SBRT (rSBRT) treatment on oligometastatic patients with liver lesions. Material and Methods: This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. The PubMed and Scopus databases were accessed by two independent investigators concerning robotic rSBRT for liver metastases, up to 3 October 2023. Results: In total, 15 studies, including 646 patients with 847 lesions that underwent rSBRT, were included in our systematic review. Complete response (CR) after rSBRT was achieved in 40.5% (95% CI, 36.66–44.46%), partial response (PR) in 19.01% (95% CI, 16.07–22.33%), whereas stable disease (SD) was recorded in 14.38% (95% CI, 11.8–17.41%) and progressive disease (PD) in 13.22% (95% CI, 10.74–16.17%) of patients. Progression-free survival (PFS) rates at 12 and 24 months were estimated at 61.49% (95% CI, 57.01–65.78%) and 32.55% (95% CI, 28.47–36.92%), respectively, while the overall survival (OS) rates at 12 and 24 months were estimated at 58.59% (95% CI, 53.67–63.33%) and 44.19% (95% CI, 39.38–49.12%), respectively. Grade 1 toxicity was reported in 13.81% (95% CI, 11.01–17.18%), Grade 2 toxicity in 5.57% (95% CI, 3.82–8.01%), and Grade 3 toxicity in 2.27% (955 CI, 1.22–4.07%) of included patients. Conclusions: rSBRT represents a promising method achieving local control with minimal toxicity in a significant proportion of patients. Further studies are needed to evaluate the role of rSBRT in the management of metastatic liver lesions. Full article
(This article belongs to the Special Issue Advances in Diagnosis and Treatment of Hepatobiliary Pancreatic Disorders)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop